The optimal treatment strategy for post-traumatic long bone non-unions is subject of an ongoing discussion. At the Maastricht University Medical Center (MUMC+) the induced membrane technique is used to treat post-traumatic long bone non-unions. This technique uses a multimodal treatment algorithm involving bone marrow aspirate concentrate (BMAC), the reamer-irrigator-aspirator (RIA) and P-15 bioactive peptide (iFactor, Cerapedics). Bioactive glass (S53P4 BAG, Bonalive) is added when infection is suspected. This study aims to objectify the effect of this treatment algorithm on the health-related quality of life (HRQoL) of patients with post-traumatic long bone non-unions. We hypothesized that HRQoL would improve after treatment.

From January 2020 to March 2023, consecutive patients who were referred to a multidisciplinary (trauma, orthopaedic and plastic surgery) non-union clinic at the MUMC+, The Netherlands, were evaluated using the Non-Union Scoring System (NUSS). The EQ-5D-5L questionnaire and the Lower Extremity Functional Scale (LEFS) were employed to obtain HRQoL outcomes both prior to and subsequent to surgery, with a follow-up at 6, 18 and 35 weeks.

Seventy-six patients were assessed at baseline (T0), with a mean NUSS of 40 (± 13 SD). Thirty-eight patients had their first follow-up, six weeks after surgery (T1). Thirty-one patients had a second follow-up at 18 weeks (T2), and twenty patients had the third follow-up at 35 weeks (T3). The EQ-5D index mean at baseline was 0.480, followed by an index of 0.618 at T1, 0.636 at T2, and 0.702 at T3. A significant difference was found in the HRQoL score between T0 and T1, as well as T2 and T3 (p<0.001; p=0.011). The mean LEFS significantly increased from 26 before intervention to 34, 39, and 43 after treatment (p<0.001; p=0.033; p=0.016).

This study demonstrated a significant improvement in the health-related quality of life of patients with post-traumatic long bone non-unions after the standardized treatment algorithm following the induced membrane technique.

The need for an artificial scaffold in very large bone defects is clear, not only to limit the risk of graft harvesting, but also to improve clinical success. The use of custom osteoconductive scaffolds made from biodegradable polyester and ceramics can be a valuable patient friendly option, especially in case of a concomitant infection.

Multiple types of scaffolds for the Masquelet procedure (MP) are available, however these frequently demonstrate central graft involution when defects exceed a certain size and the complication rates remains high. This paper describes three infected tibial defect nonunions with a segmental defect over ten centimeters long treated with a customized 3D printed polycaprolactone-tricalcium phosphate (PCL-TCP) cage in combination with biological adjuncts.

Three male patients, between the age of 37 and 47, were treated for an infected tibial defect nonunion after sustaining Gustilo grade 3 open fractures. All had a segmental midshaft bone defect of more than ten centimeters (range 11–15cm). First stage MPs consisted of extensive debridement, external fixation and placement of anterior lateral thigh flaps (ALT). Positive cultures were obtained from all patients during this first stage, that were treated with specific systemic antibiotics during 12 weeks. The second stage MP was carried out at least two months after the first stage. CT scans were obtained after the first stage to manufacture defect-specific cages. In the final procedure a custom 3D printed PCL-TCP cage (Osteopore, Singapore) was placed in the defect in combination with biological adjuncts (BMAC, RIA derived autograft, iFactor and BioActive Glass). Bridging of the defect, assessed at six months by CT, was achieved in all cases. SPECT-scans 6 months post-operatively demonstrated active bone regeneration, also involving the central part of the scaffold. All three patients regained function and reported less pain with full weight-bearing.

This case report shows that 3D printed PCL-TCP cages in combination with biological adjuncts is a novel addition to the surgical treatment of very large bone defects in (infected) posttraumatic nonunion of the tibia. This combination could overcome some of the current drawbacks in this challenging indication.

Nitric oxide is a free radical which in vivo is solely produced during the conversion of the amino acid arginine into citrulline by nitric oxide synthase enzymes. Recently, the importance of nitric oxide on inflammation and bone metabolism has been investigated. However, the knowledge regarding possible in vitro effects of arginine supplementation on chondrogenic differentiation is limited.

ATDC5, a cell line which is derived from mouse teratocarcinoma cells and which is characterized as chondrogenic cell line, were proliferated in Dulbecco's Modified Eagle Medium (DMEM)/F12 and subsequently differentiated in proliferation medium supplemented with insulin, transferrin and sodium-selenite and where arginine was added in four different concentrations (0, 7.5, 15 and 30 mM). Samples were harvested after 7 or 10 days and were stored at −80 °C for subsequent RNA isolation for qPCR analysis. To determine chondrogenic differentiation, Alcian Blue staining was performed to stain the proteoglycan aggrecan, which is secreted by differentiated ATDC5 cells. All measurements were performed in triplo.

Alcian Blue staining showed a qualitative increase of proteoglycan aggrecan secretion in differentiated ATDC5 cells after treatment with 7 and 15 mM arginine, with additional increased expression of ColII, ColX, Bmp4 and Bmp6. Treatment with 30 mM arginine inhibited chondrogenic differentiation and expression of aforementioned genes, however, Cox-2 and Vegfa gene expression were increased in these samples. Bmp7 was not significantly expressed in any experimental condition.

The obtained results are suggestive for a dose-dependent effect of arginine supplementation on chondrogenic differentiation and associated gene expression, with 7.5 and 15 mM as most optimal concentrations and implications for apoptosis after incubation with 30 mM arginine. A future recommendation would be to investigate the effects of citrulline in a similar experiment, as this shows even more promising results to enhance the nitric oxide metabolism in sepsis and bone healing.

Osteoarthritis of the first metatarsophalangeal (MTP1) joint is a common disorder in elderly, resulting in pain and disability. Arthrodesis of this joint shows satisfactory results, with relieve of pain in approximately 85% of the patients. However, the compensation mechanism for loss of motion in the MTP1 joint after MTP1 arthrodesis is unknown. A reduced compensation mechanism of the foot may explain the disappointing result of MTP1 arthrodesis in the remaining 15% of the patients. This study was conducted to elucidate this compensation mechanism. We hypothesize that the ankle and forefoot are responsible for compensation after MTP1 arthrodesis.

Gait was evaluated in eight patients with arthrodesis of the MTP1 joint (10 feet) and twelve healthy controls (21 feet) by using a sixteen-camera Vicon-system. The four-segmental, validated Oxford-Foot-Model was used to investigate differences in range of motion of the hindfoot-tibia, forefoot-hindfoot and hallux-forefoot segment during stance. For statistical analysis, the unpaired t-test with Bonferroni correction (p<0.0125) was performed.

No differences in spatiotemporal parameters were observed between both groups. In the frontal plane, MTP1 arthrodesis decreased the range of motion in midstance, while an increased range of motion was observed in terminal stance for the hindfoot relative to the tibia in the transversal plane. Subsequently range of motion in the forefoot in preswing was increased. This resulted in less eversion in the hindfoot during midstance, increased internal rotation of the hindfoot during terminal stance and more supination in the forefoot during preswing in the MTP1 arthrodesis group. Motion of the hallux was restricted in the loading response (i.e. plantar flexion) and terminal stance (i.e. dorsiflexion).

As hypothesized, both the ankle and the forefoot are responsible for compensation after MTP1 arthrodesis, because arthrodesis causes less eversion and increased internal rotation of the hindfoot and increased supination of the forefoot. As expected, both dorsiflexion and plantar flexion of the hallux was restricted due to arthrodesis. These findings suggest a gait pattern in which the lateral arch of the foot is more loaded and the stiff hallux is avoided during the stance phase of gait.

Our results indicate that proper motion of the forefoot and ankle joint is important when considering arthrodesis of the MTP1 joint. Therefore, we emphasize careful assessment the range of motion in the forefoot and ankle joint in the pre-operative situation, since patients with a decreased range of motion in the forefoot and ankle joint have a less functioning compensation mechanism. We currently perform a study to evaluate the strength of the positive correlation between the pre-operative range of motion in the forefoot and ankle joint and the clinical outcome.